Evidence map›Paper›PMID 34320022›Full record

ArticlePloS one2021

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.

Soutarou Taguchi, Hirofumi Koide, Hiroko Oiwa, Miku Hayashi, Kazuhiro Ogawa, Chihiro Ito, Koji Nakashima, Tomoko Yuasa, Akihiro Yasumoto, Hiroaki Ando and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Rasagiline, sleep quality and well-being in Parkinson's disease: a pilot study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Soutarou TaguchiParkinson's Disease Advanced Therapy Center, Aichi Medical University Hospital, Nagakute, Japan.ORCID 0000-0002-9700-4192
Hirofumi KoideDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Hiroko OiwaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Miku HayashiDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Kazuhiro OgawaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Chihiro ItoDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Koji NakashimaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Tomoko YuasaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Akihiro YasumotoDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Hiroaki AndoDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Akifumi FujikakeDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Takaaki FukuokaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Keisuke TokuiDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Masayuki IzumiDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Yuka TsunodaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Yuichi KawagashiraDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Yohei OkadaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Jun-Ichi NiwaDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Manabu DoyuDepartment of Neurology, Aichi Medical University, Nagakute, Japan.
Aichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo clarify whether antiparkinsonian drugs contribute to nocturnal sleep disturbances in patients with Parkinson's disease (PD).

backgroundAlthough the major antiparkinsonian drugs L-dopa and dopamine agonists (DAs) have been found to affect sleep, little is known about the effects of specific drugs on sleep in PD patients.

methodsThe study participants consisted of 112 PD patients (median age 72.5 years [inter-quartile range: IQR 65-79]; mean disease duration 8.44 years [standard deviation: 7.33]; median Hoehn and Yahr stage 3 [IQR 2-3.75]) taking one of three types of non-ergot extended-release DAs (rotigotine 32; pramipexole 44; ropinirole 36) with or without L-dopa (median daily total dosage of antiparkinsonian drugs 525.5 mg [IQR 376.25-658] levodopa equivalent dose [LED]). Participants were assessed using the PD Sleep Scale-2 (PDSS-2).

resultsFor the whole PD patient cohort, the PDSS-2 sleep disturbance domain score and the scores for item 1 assessing sleep quality and item 8 assessing nocturia were positively correlated with daily total dosage of antiparkinsonian drugs and dosage of L-dopa, but not with the dosage of DAs. Sub-analysis according to DA treatment revealed that DA dosage was not correlated with item 1 or 8 score in any of the subgroups. The LED ratio of rotigotine to the total dosage of antiparkinsonian drugs was inversely correlated with the item 1 score.

conclusionsThese data suggest that antiparkinsonian drugs, in particular L-dopa, adversely affect nocturnal sleep in PD patients, especially in terms of sleep quality and nocturia. Thus, adjusting both the total dosage of antiparkinsonian drugs and the dose-ratio of L-dopa might be key actions for alleviating poor sleep quality in patients with PD. Among DAs, we found a clear positive correlation between the dose-ratio of rotigotine and sleep quality. Thus, partial L-dopa replacement with rotigotine could improve sleep quality in patients with PD.

Indexed as

SleepAgedAntiparkinson AgentsCross-Sectional StudiesDopamine AgonistsHumansIndolesLevodopaParkinson DiseasePramipexoleRegression AnalysisRetrospective StudiesTetrahydronaphthalenesThiophenesAntiparkinson AgentsDopamine AgonistsIndolesLevodopaPramipexoleropinirolerotigotineTetrahydronaphthalenesThiophenes

Identifiers

PMID34320022
PMCPMC8318227
OpenAlexW3185953121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.